Bioadaptives (BDPT) Equity Ratio (2013 - 2026)

Bioadaptives has disclosed Equity Ratio across 13 years of filings, most recently posting 15.71 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 15.71, down 10.46% year-over-year; the trailing twelve-month figure through Mar 2026 was 15.71 (down 10.46% YoY), and the FY2025 annual result was 9.43, down 68.68% from the prior year.
• Equity Ratio came in at 15.71 for Q1 2026 at Bioadaptives, down from 9.43 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 3.48 in Q3 2023 to a low of 213.82 in Q2 2024.
• The 5-year median for Equity Ratio is 16.06 (2022), against an average of 38.48.
• Across the five-year window, Equity Ratio plunged 1018.35% in 2024 and soared 97.89% in 2025, its largest moves.
• Bioadaptives' Equity Ratio stood at 38.9 in 2022, then jumped by 59.3% to 15.83 in 2023, then jumped by 64.7% to 5.59 in 2024, then sank by 68.68% to 9.43 in 2025, then tumbled by 66.64% to 15.71 in 2026.
• The last three Equity Ratio figures came in at 15.71 (Q1 2026), 9.43 (Q4 2025), and 11.78 (Q3 2025), per Business Quant data.